Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac launches Late Stage Customisation Suite
Almac said that assembling regional packs results in one pack being available for as many as five markets, as country specific information is applied to the ‘Blue Box’
Almac said that assembling regional packs results in one pack being available for as many as five markets, as country specific information is applied to the ‘Blue Box’
Nintex claimed that its products which are designed to streamline standard business activities, surface valuable information, encourage and enable collaboration, and empower business users and IT professionals alike,
The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. Glycotex said that GLYC-101 is being developed to stimulate
The investigational new drug application is held by GSK. The Vivalis and GSK global collaboration and license agreement aims to develop cell-based manufacturing of seasonal and pandemic human
In the statement of intent, Eisai agreed to produce and supply to WHO free of charge up to 2.2 billion 100mg tablets of diethylcarbamazine (generic name, DEC), a
The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.
Executed in August 2008, the agreement allows Roche to develop hepatitis C viral (HCV) compounds while using Metabasis’ liver-targeting technology. Earlier, in April Roche has paid $6.5m payment
Achieve said that the research studies will enroll those already diagnosed with IBS, which includes symptoms like pain or discomfort in the abdomen, drastic change in the frequency
Teva claims that Prednisolone EC tablets are a generic version of Deltacortril from Alliance Pharmaceuticals and are indicated in the treatment of inflammatory and allergic conditions such as
Eli Lilly and Acrux claim that Axiron is the first testosterone topical solution approved for application via an armpit (underarm) applicator. Lilly USA president David Ricks said that